Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Probable polyketide synthase Pks1 | 0.0446 | 0.2588 | 0.3461 |
Mycobacterium ulcerans | Type I modular polyketide synthase | 0.0621 | 0.4361 | 0.5834 |
Mycobacterium leprae | Probable polyketide synthase Pks1 | 0.0659 | 0.4752 | 0.6337 |
Toxoplasma gondii | beta-ketoacyl synthase, N-terminal domain-containing protein | 0.0403 | 0.2149 | 0.2574 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsC | 0.0659 | 0.4752 | 0.6357 |
Loa Loa (eye worm) | hypothetical protein | 0.1043 | 0.8643 | 1 |
Mycobacterium tuberculosis | Phenolpthiocerol synthesis type-I polyketide synthase PpsC | 0.0621 | 0.4361 | 0.5834 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks15 | 0.0251 | 0.061 | 0.0817 |
Mycobacterium ulcerans | polyketide synthase | 0.0621 | 0.4361 | 0.5834 |
Mycobacterium ulcerans | multifunctional mycocerosic acid synthase membrane-associated Mas | 0.0659 | 0.4752 | 0.6357 |
Brugia malayi | AMP-binding enzyme family protein | 0.058 | 0.3948 | 0.3948 |
Mycobacterium tuberculosis | Polyketide synthase Pks13 | 0.0928 | 0.7476 | 1 |
Mycobacterium tuberculosis | Probable multifunctional mycocerosic acid synthase membrane-associated Mas | 0.0659 | 0.4752 | 0.6357 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsA | 0.0499 | 0.3131 | 0.4188 |
Mycobacterium leprae | PROBABLE THIOESTERASE TESA | 0.0517 | 0.3311 | 0.4398 |
Onchocerca volvulus | 0.108 | 0.9025 | 0.9285 | |
Mycobacterium ulcerans | polyketide synthase | 0.0659 | 0.4752 | 0.6357 |
Loa Loa (eye worm) | hypothetical protein | 0.0348 | 0.1592 | 0.0823 |
Mycobacterium tuberculosis | Phenolpthiocerol synthesis type-I polyketide synthase PpsD | 0.0621 | 0.4361 | 0.5834 |
Mycobacterium ulcerans | thioesterase | 0.0517 | 0.3311 | 0.443 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSA | 0.0621 | 0.4361 | 0.581 |
Mycobacterium tuberculosis | Phenolpthiocerol synthesis type-I polyketide synthase PpsA | 0.0621 | 0.4361 | 0.5834 |
Mycobacterium tuberculosis | Probable membrane bound polyketide synthase Pks6 | 0.0928 | 0.7476 | 1 |
Mycobacterium tuberculosis | Polyketide synthase Pks12 | 0.0659 | 0.4752 | 0.6357 |
Mycobacterium tuberculosis | Probable fatty acid synthase Fas (fatty acid synthetase) | 0.0195 | 0.0042 | 0.0056 |
Mycobacterium tuberculosis | Phenyloxazoline synthase MbtB (phenyloxazoline synthetase) | 0.058 | 0.3948 | 0.528 |
Mycobacterium leprae | Probable multifunctional mycocerosic acid synthase membrane associated enzyme Mas | 0.0659 | 0.4752 | 0.6337 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks5 | 0.0602 | 0.4168 | 0.5576 |
Toxoplasma gondii | type I fatty acid synthase, putative | 0.0442 | 0.2547 | 0.3708 |
Mycobacterium ulcerans | polyketide synthase Pks13 | 0.0928 | 0.7476 | 1 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSC | 0.0659 | 0.4752 | 0.6337 |
Brugia malayi | Beta-ketoacyl synthase, N-terminal domain containing protein | 0.0621 | 0.4361 | 0.4361 |
Mycobacterium ulcerans | fatty acid synthase Fas | 0.0195 | 0.0042 | 0.0056 |
Mycobacterium tuberculosis | Polyketide synthase Pks2 | 0.0602 | 0.4168 | 0.5576 |
Mycobacterium ulcerans | Type I modular polyketide synthase | 0.0621 | 0.4361 | 0.5834 |
Toxoplasma gondii | type I fatty acid synthase, putative | 0.0659 | 0.4752 | 1 |
Loa Loa (eye worm) | fatty acid synthase | 0.0612 | 0.4277 | 0.4318 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSD | 0.0621 | 0.4361 | 0.581 |
Mycobacterium ulcerans | Type I modular polyketide synthase | 0.0621 | 0.4361 | 0.5834 |
Schistosoma mansoni | serine-type protease inhibitor | 0.0532 | 0.3462 | 0.5 |
Mycobacterium tuberculosis | Probable thioesterase TesA | 0.0517 | 0.3311 | 0.443 |
Mycobacterium tuberculosis | Polyketide synthetase MbtC (polyketide synthase) | 0.0213 | 0.0229 | 0.0306 |
Mycobacterium ulcerans | polyketide synthase Pks9 | 0.041 | 0.2228 | 0.2981 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSE | 0.041 | 0.2228 | 0.2941 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks9 | 0.0353 | 0.1644 | 0.2199 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks8 | 0.0508 | 0.3214 | 0.4299 |
Onchocerca volvulus | Fatty acid synthase homolog | 0.1119 | 0.9416 | 1 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsD | 0.0621 | 0.4361 | 0.5834 |
Mycobacterium tuberculosis | Probable polyketide synthase Pks7 | 0.0659 | 0.4752 | 0.6357 |
Mycobacterium ulcerans | thioesterase TesA | 0.0517 | 0.3311 | 0.443 |
Loa Loa (eye worm) | AMP-binding enzyme family protein | 0.058 | 0.3948 | 0.3889 |
Schistosoma mansoni | serine-type protease inhibitor | 0.0532 | 0.3462 | 0.5 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsB | 0.0499 | 0.3131 | 0.4188 |
Mycobacterium ulcerans | phenolpthiocerol synthesis type-I polyketide synthase PpsE | 0.041 | 0.2228 | 0.2981 |
Mycobacterium leprae | Polyketide synthase Pks13 | 0.0928 | 0.7476 | 1 |
Mycobacterium leprae | PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSB | 0.0499 | 0.3131 | 0.4155 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 2.7 uM | Inhibition of [3H]-thymidine incorporation into the DNA of uninfected HeLa cells | ChEMBL. | 7752206 |
IC50 (functional) | = 3.4 uM | Inhibition against DNA of uninfected HEL cells by incorporation of [3H]-TdR. | ChEMBL. | 7752205 |
IC50 (functional) | = 7.9 uM | Inhibition of human CMV DNA synthesis in CMV-infected HEL cells. | ChEMBL. | 7752205 |
IC50 (functional) | = 23 uM | Inhibition of HSV-1 DNA synthesis in virus-infected HeLa cells | ChEMBL. | 7752206 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 7752205 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.